DNTHDianthus TherapeuticsSigning up patients
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Myasthenia Gravis, Generalized
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 195 (planned)
- Started
- Jun 29, 2026
- Main results expected
- Dec 2028
- Fully finished
- Sep 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Change from Baseline to Week 17 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale Score
Measured over: Baseline (Day 1) to Week 17
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07647510 · record last updated 2026-10-30 · checked 2026-11-09 15:36 UTC